welcome to STERNA BIOLOGICALS
Treatment of type 2 inflammatory diseases by GATA-3 downregulation
LATEST PRESS RELEASES
sterna biologicals raises further EUR 10.0 million (approx. USD 11.9 million) in series A - 2nd closing private placement
Marburg, Germany, January 07, 2021 Following successful completion of the company’s Series A – 1st closing with EUR 12.0 million in April 2020, sterna now has successfully completed a 2nd closing with another EUR 10.0 million, bringing the Series A total to EUR 22.0 million Proceeds from the 2nd closing will fund phase IIb preparatory activities including toxicology studies and CMC work for ...
READ MOREsterna biologicals to attend international partnering and investor conferences in November
Marburg, Germany, November 07, 2019 Sterna biologicals GmbH & Co. KG (“sterna”), an innovative clinical-stage immunology company developing novel treatments for chronic inflammatory diseases, today announced that the Company will participate and present at the following partnering and investor conferences in November: ...
READ MOREsterna biologicals secures EUR 12.0 million (approx. USD 13.0 million) in private placement
Marburg, Germany, May 26, 2020 Proceeds to fund next Phase 2 clinical study with SB010 in moderate to severe asthma and oral formulation work for SB012 in ulcerative colitis Sterna’s approach to down-regulate master transcription factor GATA-3 using a DNAzyme (enzymatic antisense oligonucleotide) enables broad-spectrum, simultaneous intervention in key type 2 inflammatory processes Topical ...
READ MOREsterna biologicals invited to present at the GOODWIN - SOLEBURY TROUT - NASDAQ european biotech investor day 2019
Marburg, Germany, 25 July 2019 sterna biologicals selected as one of a group of top-tier European biotech companies to present at the European Biotech Investor Day on August 1, 2019 in New York City CEO Christian Pangratz to discuss the Company’s robust development progress and next phase of growth fueled by sterna’s first-in-class DNAzyme hgd40 in Phase 2 development for asthma and ulcerative ...
READ MOREsterna biologicals strengthens management team to progress towards phase IIB development
Marburg, Germany, 08 July 2019 Industry veteran Dr. Marion Wencker strengthens sterna’s management team as consulting CMO Financial expert Dr. Thomas Klaue recently joined sterna as consulting CFO sterna biologicals GmbH & Co. KG (Sterna), an innovative clinical-stage immunology company developing novel biological treatments for chronic inflammatory diseases, announced today that the Company has ...
READ MORE
sterna biologicals
sterna biologicals is an innovative clinical-stage immunology company developing novel immunomodulation therapies for patients suffering from type 2 inflammatory diseases.
The GATA-3 Approach
GATA-3 is a key master transcription factor in type 2 inflammation. GATA-3 downregulation could provide a novel, first-in-class anti-inflammatory treatment approach.
Pipeline
sterna biologicals has a clinically validated development pipeline with lead candidates in asthma and ulcerative colitis.
BIO-Europe
Spring 2021
March 22–25, 2021
Delivered Digitally
